These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 21864624)

  • 21. Safety and immunogenicity of two different doses of a Vero cell-derived, whole virus clade 2 H5N1 (A/Indonesia/05/2005) influenza vaccine.
    Tambyah PA; Wilder-Smith A; Pavlova BG; Barrett PN; Oh HM; Hui DS; Yuen KY; Fritsch S; Aichinger G; Loew-Baselli A; van der Velden M; Maritsch F; Kistner O; Ehrlich HJ
    Vaccine; 2012 Jan; 30(2):329-35. PubMed ID: 22080174
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immune enhancing properties of the novel Matrix-M™ adjuvant leads to potentiated immune responses to an influenza vaccine in mice.
    Magnusson SE; Reimer JM; Karlsson KH; Lilja L; Bengtsson KL; Stertman L
    Vaccine; 2013 Mar; 31(13):1725-33. PubMed ID: 23384754
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cell culture (Vero cell) derived whole-virus non-adjuvanted H5N1 influenza vaccine induces long-lasting cross-reactive memory immune response: homologous or heterologous booster response following two dose or single dose priming.
    van der Velden MV; Aichinger G; Pöllabauer EM; Löw-Baselli A; Fritsch S; Benamara K; Kistner O; Müller M; Zeitlinger M; Kollaritsch H; Vesikari T; Ehrlich HJ; Barrett PN
    Vaccine; 2012 Sep; 30(43):6127-35. PubMed ID: 22884662
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunological priming induced by a two-dose series of H5N1 influenza antigen, administered alone or in combination with two different formulations of AS03 adjuvant in adults: results of a randomised single heterologous booster dose study at 15 months.
    Risi G; Frenette L; Langley JM; Li P; Riff D; Sheldon E; Vaughn DW; Fries L
    Vaccine; 2011 Aug; 29(37):6408-18. PubMed ID: 21554915
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Homologous and heterologous antibody responses to a one-year booster dose of an MF59(®) adjuvanted A/H5N1 pre-pandemic influenza vaccine in pediatric subjects.
    Vesikari T; Forstén A; Borkowski A; Gaitatzis N; Banzhoff A; Clemens R
    Hum Vaccin Immunother; 2012 Jul; 8(7):921-8. PubMed ID: 22777094
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunogenicity and Safety of H5N1 A/Vietnam/1194/2004 (Clade 1) AS03-adjuvanted prepandemic candidate influenza vaccines in children aged 3 to 9 years: a phase ii, randomized, open, controlled study.
    Díez-Domingo J; Garcés-Sanchez M; Baldó JM; Planelles MV; Ubeda I; JuBert A; Marés J; Moris P; Garcia-Corbeira P; Dramé M; Gillard P
    Pediatr Infect Dis J; 2010 Jun; 29(6):e35-46. PubMed ID: 20375709
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A phase III, randomized, open-label study to assess the tolerability and immunogenicity of an H5N1 influenza vaccine administered to healthy adults with a 1-, 2-, 3-, or 6-week interval between first and second doses.
    Beran J; Abdel-Messih IA; Raupachova J; Hobzova L; Fragapane E
    Clin Ther; 2010 Dec; 32(13):2186-97. PubMed ID: 21316535
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults.
    Levie K; Leroux-Roels I; Hoppenbrouwers K; Kervyn AD; Vandermeulen C; Forgus S; Leroux-Roels G; Pichon S; Kusters I
    J Infect Dis; 2008 Sep; 198(5):642-9. PubMed ID: 18576945
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Matrix-M adjuvanted virosomal H5N1 vaccine confers protection against lethal viral challenge in a murine model.
    Pedersen G; Major D; Roseby S; Wood J; Madhun AS; Cox RJ
    Influenza Other Respir Viruses; 2011 Nov; 5(6):426-37. PubMed ID: 21668670
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunogenicity and safety of low dose virosomal adjuvanted influenza vaccine administered intradermally compared to intramuscular full dose administration.
    Künzi V; Klap JM; Seiberling MK; Herzog C; Hartmann K; Kürsteiner O; Kompier R; Grimaldi R; Goudsmit J
    Vaccine; 2009 Jun; 27(27):3561-7. PubMed ID: 19464535
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combined, concurrent, and sequential administration of seasonal influenza and MF59-adjuvanted A/H5N1 vaccines: a phase II randomized, controlled trial of immunogenicity and safety in healthy adults.
    Lopez P; Caicedo Y; Sierra A; Tilman S; Banzhoff A; Clemens R
    J Infect Dis; 2011 Jun; 203(12):1719-28. PubMed ID: 21606530
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunogenicity and tolerability of an AS03(A)-adjuvanted prepandemic influenza vaccine: a phase III study in a large population of Asian adults.
    Chu DW; Hwang SJ; Lim FS; Oh HM; Thongcharoen P; Yang PC; Bock HL; Dramé M; Gillard P; Hutagalung Y; Tang H; Teoh YL; Ballou RW;
    Vaccine; 2009 Dec; 27(52):7428-35. PubMed ID: 19683087
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intramuscular Matrix-M-adjuvanted virosomal H5N1 vaccine induces high frequencies of multifunctional Th1 CD4+ cells and strong antibody responses in mice.
    Madhun AS; Haaheim LR; Nilsen MV; Cox RJ
    Vaccine; 2009 Dec; 27(52):7367-76. PubMed ID: 19781678
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial.
    Roman F; Vaman T; Gerlach B; Markendorf A; Gillard P; Devaster JM
    Vaccine; 2010 Feb; 28(7):1740-5. PubMed ID: 20034605
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A clinical trial of a whole-virus H5N1 vaccine derived from cell culture.
    Ehrlich HJ; Müller M; Oh HM; Tambyah PA; Joukhadar C; Montomoli E; Fisher D; Berezuk G; Fritsch S; Löw-Baselli A; Vartian N; Bobrovsky R; Pavlova BG; Pöllabauer EM; Kistner O; Barrett PN;
    N Engl J Med; 2008 Jun; 358(24):2573-84. PubMed ID: 18550874
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and immunogenicity of a modified-vaccinia-virus-Ankara-based influenza A H5N1 vaccine: a randomised, double-blind phase 1/2a clinical trial.
    Kreijtz JH; Goeijenbier M; Moesker FM; van den Dries L; Goeijenbier S; De Gruyter HL; Lehmann MH; Mutsert Gd; van de Vijver DA; Volz A; Fouchier RA; van Gorp EC; Rimmelzwaan GF; Sutter G; Osterhaus AD
    Lancet Infect Dis; 2014 Dec; 14(12):1196-207. PubMed ID: 25455987
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1, NIBRG-14) vaccine administered by intramuscular or subcutaneous injection.
    Ikeno D; Kimachi K; Kino Y; Harada S; Yoshida K; Tochihara S; Itamura S; Odagiri T; Tashiro M; Okada K; Miyazaki C; Ueda K
    Microbiol Immunol; 2010 Feb; 54(2):81-8. PubMed ID: 20377741
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessment of antigen-specific and cross-reactive antibody responses to an MF59-adjuvanted A/H5N1 prepandemic influenza vaccine in adult and elderly subjects.
    Bihari I; Pánczél G; Kovacs J; Beygo J; Fragapane E
    Clin Vaccine Immunol; 2012 Dec; 19(12):1943-8. PubMed ID: 23081815
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The safety and immunogenicity of a cell-derived adjuvanted H5N1 vaccine - A phase I randomized clinical trial.
    Cheng A; Hsieh SM; Pan SC; Li YH; Hsieh EF; Lee HC; Lin TW; Lai KL; Chen C; Shi-Chung Chang S; Chang SC
    J Microbiol Immunol Infect; 2019 Oct; 52(5):685-692. PubMed ID: 31255574
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial.
    Leroux-Roels I; Borkowski A; Vanwolleghem T; Dramé M; Clement F; Hons E; Devaster JM; Leroux-Roels G
    Lancet; 2007 Aug; 370(9587):580-9. PubMed ID: 17707753
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.